SUMMARY The technique of polarised light goniometry was used to quantify objectively parameters of the spastic gait during a double-blind cross-over trial comparing the spasniolytic effects of DS 103-282, baclofen and placebo. Only minimal objective and subjective changes in gait were found when the results of treatment with DS103-282 or haclofen were compared with those of treatment with placebo.
obtained by treating patients with baclofen and with a placebo.
Methods
Ten patients were studied. Clinical details are given in table 1. All were selected from a routine neurological outpatient clinic. The criteria for selection were the presence of an abnormal gait due to lower limb spasticity which was non-progressive and which had been stable for at least two months prior to the start of the trial. Informed consent was obtained from all patients. Only three patients (numbers 4, 8, and 9) had previously received a spasmolytic agent (baclofen) and no subjective benefit had been reported at the dosage used. During the trial the dosage of baclofen tolerated was the same as had previously been used for patient number 4 but patients number 8 and 9 tolerated double the previous dosage. A doubleblind cross-over design was used. Each patient received the'highest dose of drug that he could tolerate, up to a maximum of 60 mg per day of baclofen and 24 mg per day of DS103-282, for a two week period. A two week "wash-out" period was allowed between the administration of either drug during which time a placebo was given. The maximum tolerated dose of drug was determined during a non-blind run-in phase. Details of the doses used are given in table 1. None of the patients was At each visit the strength of hip flexion and knee extension was graded according to the MRC scale. General mobility was assessed and graded thus: 2-fully mobile, 1-mobile but housebound, 0-chairbound. Spasms in the lower limbs during the treatment period were graded thus: 0-no spasm, 1-moderate, 2-severe spasms. Urinary frequency was graded thus: 2-severe frequency, 1-frequency present, 0-normal micturition.
In addition the patient was asked to assess whether there had been any improvement of deterioration in the stiffness in their legs. To assess subjectively the degree to which walking was affected by spasticity the patient was asked to grade the effect of stiffness on gait as follows: 1-interferes slightly, 2-interferes moderately, 3-interferes severely with walking. The inclinations of the foot, calf and thigh were measured using a polarised light goniometer (Crane Electronics Ltd) with three transducers. Three angles (fig 1) were recorded while the subjects walked barefoot along a level surface. Recording was achieved over the central five metres of a seven metre walkway and the patients were asked to repeat the walk until at least twelve complete swing phases were measured. Both right and left limb movements were recorded. Data from the goniometer were acquired at a rate of 100 samples per second and transcribed to permanent digital storage for further analysis. The ankle and knee angles were computed from the three recorded angles.
Initially an attempt was made to record the time of heel strike (HS) and toe off (TO) using small pressure switches taped to the sole of the foot. This was found to give unreliable measurements and was abandoned in favour of manual selection of swing phase, using the ankle and knee . Whilst it was appreciated that this manual method could be prone to error, it was found in practice that repeatability of swing phase time definition was superior to using footswitch events. Following definition of swing phase location, the first twelve such artefact-free events were selected from each set of data. Each swing phase was then analysed for the fifteen measures illustrated in fig 3. The means and standard errors for each measure and for both limbs were computed for each visit of the subject. The standard errors were found to be small relative to the variability between subjects or between visits. Thus the final analysis of the data used a two-way analysis of variance for each measure based upon the mean values determined for each visit and each limb.
-ND The lower the score the less walking was impaired by stiffness. Duration of swing phase 0-7 0 7 0-6 0 7 0-7 0-7 0 7 0-7 -indicates flexion at the knee joint and plantar flexion at the ankle joint.
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ANALYSIS
Mean values for all the parameters measured are shown in tables 5 and 6. There were few parameters which altered when the patient was receiving placebo, baclofen or DS103-282. For the right leg the ankle angle at heel strike was more plantar flexed (p < 005) when the patients were taking DS103-282 and more dorsiflexed (p < 0 05) when taking baclofen. In addition the knee angle at toe off was more extended when the patients were taking DS103-282 or baclofen (< 001) than when taking no treatment or placebo. For the left leg the knee peak angle was more flexed (p < 0 05) when the patients were taking a placebo, DS103-282 or baclofen than when no treatment was being given.
Discussion
In the assessment of the value of drug treatment for spasticity an objective measurement should provide greater accuracy than either the patients subjective experience or clinical examination. The objective method of assessment used should measure parameters which directly relate to the symptoms that it is hoped to improve.
In ambulant patients drugs to relieve spasticity are usually given to improve gait yet most objective methods used to evaluate such drugs do not measure parameters of gait but rather determine spasticity in muscles which are passively stretched.3 Since there is evidence that the response of spastic muscles to lengthening differs during passive and voluntary movement4 alterations in spasticity measured by such techniques may not accurately reflect changes which occur during walking. During a complex activity such as walking there may be a further modification of reflex activity and the response to drugs may therefore be different from that obtained in experimental situations involving only passive flexion and extension. Objective measurement of parameters of the spastic gait should therefore permit a better assessment of the value of an antispasticity drug in ambulant patients.
Measurement of parameters of gait in spasticity is based upon the fact that spasticity reduces the range and velocity of movement of limbs. Relief of spasticity, therefore, in the absence of excessive weakness, should result in movement which is greater in range and velocity. 
